Taizhou Mabtech Pharmaceutical Co.,Ltd
16
2
5
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
12.5%
2 terminated/withdrawn out of 16 trials
81.8%
-4.7% vs industry average
25%
4 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers
Role: lead
To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria
Role: lead
Comparative Study of EnliTuo® Before and After Technology Change in Healthy Male Volunteers
Role: lead
Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis
Role: lead
Compare the PK, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in Healthy Adult Male Subjects
Role: lead
Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors
Role: lead
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer
Role: lead
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
Role: lead
Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy Volunteers
Role: lead
Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers
Role: lead
Study of CMAB807X Pre- and Post-change in Manufacturing Site and Xgeva® in Healthy Volunteers
Role: lead
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC
Role: lead
The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and Immunogenicity
Role: lead
The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety
Role: lead
The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety
Role: lead
Pharmacokinetic, Safety and Immunogenicity Study of CMAB809 and Herceptin in Healthy Volunteers
Role: lead
All 16 trials loaded